CTRI/2022/03/041200已完成1 期
A Phase I, Double Blind, Randomized, Parallel-group, Single dose, Three arm, Comparative Pharmacokinetic and Pharmacodynamic Study of Dr. Reddyâ??s Tocilizumab (DRL_TC), USA sourced reference Tocilizumab (Actemra) and EU sourced reference Tocilizumab (RoActemra) administered by the Intravenous route to Normal Healthy Male Vounteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 141
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Healthy male volunteers, 18 to 50 years (both inclusive) of age
- •2.In general good health as determined by a qualified physician based on a comprehensive medical history, physical examination including vital signs, laboratory hematology, clinical chemistry, urinalysis and 12-lead ECG before randomisation
- •3.Body mass index between 18.5-30.0 kg/m2 (both inclusive) and body weight of 50.0 â?? 90.0 kg (both inclusive)
- •4.Have all screening results (vital signs, physical examination, clinical laboratory tests, 12-lead ECG, thyroid function etc.) within the normal range or outside the normal range but assessed as clinically non-significant by the Investigator unless the value constitutes an explicit exclusion criterion.
- •5.Volunteers must be willing to abstain from sexual intercourse or willing to use adequate contraception in all relationships with a partner from the opposite sex a condom for the male partner and another form of contraception (such as an intra-uterine device, barrier method with spermicide, oral contraceptive, injectable progesterone, sub-dermal implant) for the female partner from the time of screening until 3 months after the dosing date unless one of the partners is infertile or surgically sterile.
- •6. Capable, and amenable to providing written informed consent to the study requirements
- •7.Willing to stay on study restrictions throughout the study duration
排除标准
- •1.Positive test result for Quantiferon- TB Gold test, syphilis, hepatitis B, hepatitis C, or HIV-1 or 2.
- •2.Live virus vaccination within 3 months prior to screening or intention to receive live virus vaccination during the trial or up to 3 months after the administration of the study drug.
- •3.Any prior exposure to tocilizumab or to any other agents directly acting on interleukin-6 or on its receptors including investigational products.
- •4. History of immunodeficiency or other clinically significant immunological disorders, or auto-immune disorders, ongoing or frequent/ recurring infection defined as more than 3/year requiring treatment or prior herpes zoster not fully healed (including the post-herpetic neuralgia period if occurring) within one year prior to randomisation or history of systemic fungal infection at any time.
- •5.Allergy or hypersensitivity to any recombinant human or humanized antibodies, other therapeutic proteins or any excipients in the study formulations.
- •6.History and/or current presence of clinically significant (in the opinion of the Investigator) atopic allergy, hypersensitivity or allergic reactions.
- •7.Blood donation, participation in any study requiring repeated blood sampling or haemorrhage requiring treatment or any transfusion in the past 3 months.
- •8.Screening or baseline (day -1) blood pressure higher than 140 mm Hg (systolic) or higher than 90 mm Hg (diastolic) or subjects currently on anti-hypertensive drugs. Up to two repeats in different days are allowed and, in this case, the mean of the measurements will be used to decide on eligibility. Screening blood pressure is to be measured in the sitting position after 5 minutes rest on the same.
- •9.History of relevant orthostatic hypotension, fainting spells, or blackouts.
- •10.QTc (Fridericia correction) longer than 450 milliseconds.
- •11.History or presence of any clinically relevant nervous system disease including, but not restricted to any stroke/TIA or of seizures other than febrile seizures before the age of 5 years.
- •12.History of and/or current gastrointestinal, renal, endocrine, pulmonary, hepatic, cardiovascular (including history of or presence of angina, exertional dyspnea, orthopnea, congestive heart failure or myocardial infarction and thrombotic or embolic episode requiring treatment), haematological (including pancytopenia, aplastic anemia or blood dyscrasia and coagulopathies or an INR higher than 1.5), metabolic (including known diabetes mellitus) considered as significant by the investigator. This criterion includes any disorder or condition that, in the Investigatorâ??s opinion, may interfere with the safety of the subject, the study evaluations or the subject compliance to the study procedures and limitations
- •13.ALT or AST higher than 1.25 times the ULN (a single repeat in a different day is allowed).
- •14.Absolute Neutrophil count below 2 x 109/liter (2000 per mm3) or platelet count below 100 x 109/liter (100000 per mm3). A single repeat in a different day is allowed.
- •15.Clinically relevant hyperlipidaemia (fasting serum LDL-cholesterol higher than 190 mg/dL or fasting serum triglycerides higher than 220 mg/dL or subject currently on antihyperlipidaemic drugs). A single repeat in a different day is allowed.
- •16.Any active infection, even if minor, ongoing at the time of screening or dosing.
- •17.Presence of any non-healed wound or bone f
研究者
相似试验
已完成
不适用
A Phase 1, Single-blind, Randomized, Parallel-group Study in Healthy Participants to Investigate the Single-dose Pharmacokinetics, Safety and Tolerability of Rilpivirine After Subcutaneous Administration of a Rilpivirine Extended-Release Suspension alone, and of Rilpivirine and Cabotegravir After Co-administration with Cabotegravir Extended-Release SuspensioNL-OMON51507Janssen-Cilag International NV60
已完成
1 期
A study to establish biosimilarity of HD201 to Herceptin when administered to healthy male participantsCancer - BreastBreast cancerACTRN12619000220167Prestige BioPharma Australia Pty Ltd105
已完成
不适用
A Phase I, Randomized, Double-Blind, Parallel Group, Single-Dose Trial to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Two Formulations of MSB11022 (Proposed Adalimumab Biosimilar)<br>biosimilarHealthy Volunteers (arthritis, skin conditions, digestive disorders)anti inflammationNL-OMON43181Merck30
进行中（未招募）
2 期
Study to evaluate the safety and efficacy of single-dose of intravenously administered Dengue monoclonal antibody in Adults with Dengue FeverCTRI/2021/07/035290Serum Institute of India Pvt Ltd
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with uncontrolled asthmaSevere AsthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-002069-21-GBAstraZeneca AB110